These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
267 related articles for article (PubMed ID: 11024226)
1. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Krattenmacher R Contraception; 2000 Jul; 62(1):29-38. PubMed ID: 11024226 [TBL] [Abstract][Full Text] [Related]
2. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Fuhrmann U; Krattenmacher R; Slater EP; Fritzemeier KH Contraception; 1996 Oct; 54(4):243-51. PubMed ID: 8922878 [TBL] [Abstract][Full Text] [Related]
3. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Muhn P; Fuhrmann U; Fritzemeier KH; Krattenmacher R; Schillinger E Ann N Y Acad Sci; 1995 Jun; 761():311-35. PubMed ID: 7625729 [TBL] [Abstract][Full Text] [Related]
4. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. Oelkers W; Foidart JM; Dombrovicz N; Welter A; Heithecker R J Clin Endocrinol Metab; 1995 Jun; 80(6):1816-21. PubMed ID: 7775629 [TBL] [Abstract][Full Text] [Related]
5. Evolution of progestins. Focus on the novel progestin drospirenone. Thorneycroft IH J Reprod Med; 2002 Nov; 47(11 Suppl):975-80. PubMed ID: 12497671 [TBL] [Abstract][Full Text] [Related]
6. Drospirenone in combination with estrogens: for contraception and hormone replacement therapy. Oelkers WH Climacteric; 2005 Oct; 8 Suppl 3():19-27. PubMed ID: 16203652 [TBL] [Abstract][Full Text] [Related]
7. Pharmacology of different progestogens: the special case of drospirenone. Sitruk-Ware R Climacteric; 2005 Oct; 8 Suppl 3():4-12. PubMed ID: 16203650 [TBL] [Abstract][Full Text] [Related]
8. Antimineralocorticoid activity of a novel oral contraceptive containing drospirenone, a unique progestogen resembling natural progesterone. Oelkers W Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():19-26; discussion 42-3. PubMed ID: 12659403 [TBL] [Abstract][Full Text] [Related]
10. Drospirenone--a new progestogen with antimineralocorticoid activity, resembling natural progesterone. Oelkers W Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():17-24. PubMed ID: 11246598 [TBL] [Abstract][Full Text] [Related]
11. Effect of an oral contraceptive containing drospirenone on the renin-angiotensin-aldosterone system in healthy female volunteers. Oelkers W; Helmerhorst FM; Wuttke W; Heithecker R Gynecol Endocrinol; 2000 Jun; 14(3):204-13. PubMed ID: 10923282 [TBL] [Abstract][Full Text] [Related]
12. An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Parsey KS; Pong A Contraception; 2000 Feb; 61(2):105-11. PubMed ID: 10802275 [TBL] [Abstract][Full Text] [Related]
13. Added benefits of drospirenone for compliance. Foidart JM Climacteric; 2005 Oct; 8 Suppl 3():28-34. PubMed ID: 16203653 [TBL] [Abstract][Full Text] [Related]
14. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Pharmacological characterization in animal models. Muhn P; Krattenmacher R; Beier S; Elger W; Schillinger E Contraception; 1995 Feb; 51(2):99-110. PubMed ID: 7750297 [TBL] [Abstract][Full Text] [Related]
15. Advances in hormone replacement therapy: weight benefits of drospirenone, a 17alpha-spirolactone-derived progestogen. Foidart JM; Faustmann T Gynecol Endocrinol; 2007 Dec; 23(12):692-9. PubMed ID: 18075844 [TBL] [Abstract][Full Text] [Related]
16. Conception and pharmacodynamic profile of drospirenone. Elger W; Beier S; Pollow K; Garfield R; Shi SQ; Hillisch A Steroids; 2003 Nov; 68(10-13):891-905. PubMed ID: 14667981 [TBL] [Abstract][Full Text] [Related]
17. Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure. Oelkers WK Steroids; 1996 Apr; 61(4):166-71. PubMed ID: 8732994 [TBL] [Abstract][Full Text] [Related]
18. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives]. Cianci A; De Leo V Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832 [TBL] [Abstract][Full Text] [Related]
19. Effects of drospirenone on cardiovascular markers in human aortic endothelial cells. Seeger H; Wallwiener D; Mueck AO Climacteric; 2009 Feb; 12(1):80-7. PubMed ID: 18979300 [TBL] [Abstract][Full Text] [Related]
20. Effects of a combined oral contraceptive containing 20 mcg of ethinylestradiol and 3 mg of drospirenone on the blood pressure, renin-angiotensin-aldosterone system, insulin resistance, and androgenic profile of healthy young women. Giribela CR; Consolim-Colombo FM; Nisenbaum MG; Moraes TL; Giribela AH; Baracat EC; Melo NR Gynecol Endocrinol; 2015; 31(11):912-5. PubMed ID: 26172927 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]